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Identity 
Other names: BDB, BDB1, MGC163394, NTRKR2 
HGNC (Hugo): ROR2 
Location: 9q22.31 
Local order: Orientation: minus strand. 
DNA/RNA 
Description 
ROR2 contains 9 exons and is 227561 base pairs (via 
GeneLoc). 
Transcription 




The ROR2 protein product is 943 amino acids with the 
molecular weight estimated to be 104.76 kDa. 
Expression 
ROR2 is a developmentally expressed kinase with hig
expression normally seen throughout the body 
including the face, limb buds, heart, lungs and brain 
(Takeuchi et al., 2000; Matsuda et al., 2001). 
Expression of ROR2 begins to abate at approximately 
day 16 of development (Yoda et al., 2003). 
In adult tissues, ROR2 is normally undetectable or 
expressed at very low levels. Functional ROR2 
expression has been confirmed in the mouse cycling 
and pregnant uterus (Hatta et al., 2010). In humans, 
ROR2 cDNA has been detected in the uterus as well as 
the parathyroid and testis (Katoh et al., 2005). ROR2 
has further been found to be upregulated as pluripotent 
cells emerge as pre-osteoblasts, and to be 
downregulated again as cells differentiate into 
osteocytes (Billiard et al., 2005). 
Localisation 
ROR2 is a single-pass type I membrane protein 
(Masiakowski et al., 1992) with localization restric ed 
to the membrane. 
 
Extracellularly, ROR2 contains an Ig-like domain (Ig), a frizzled or cysteine-rich (CRD) domain shown to act as a receptor for Wnt and a 
kringle (Kr) domain. The extracellular and intracellular domains are separated by a transmembrane (TM) domain. Intracellularly, ROR2 
contains a tyrosine kinase (TK) domain and a proline-rich domain (PR) flanked by serine/threonine (ST) rich domains. 
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Function 
ROR2 is a tyrosine protein kinase receptor highly 
implicated in development. It has also been implicated 
in the early formation of chondrocytes (DeChiara et l., 
2000; Takeuchi et al., 2000). ROR2 is thought to play a 
key role in cartilage and growth plate development 
(DeChiara et al., 2000). The Wnt signaling pathway h s
also emerged as a key target of ROR2 activity. More 
specifically, evidence suggests that Wnt5a utilizes 
ROR2 as a receptor or co-receptor for its noncanonical 
Wnt mediated signaling (Minami et al., 2010; Sato e 
al., 2010). Additionally, recent evidence suggests that 
ROR2 is expressed and plays a role in various cancer 
etiologies including gastric cancer, renal cell 
carcinoma, malignant melanoma, and prostate cancer. 
Homology 
ROR2 is highly conserved across several species - from 
C. elegans to D. melanogaster to M. musculus to H. 
sapiens. For example, there is a 92% amino acid 




Robinow syndrome and Brachydactyl type B (BDB) 
are two genetic disorders that arise from mutations in 
ROR2:  
1) Robinow syndrome is an autosomal recessive 
disorder that arises from nonsense, missense and 
frameshift mutations in the kringle, CRD and kinase 
domains - and is thought to cause a loss of functio of 
ROR2 (Afzal et al., 2000). Those that present with 
Robinow syndrome have skeletal development defects 
(van Bokhoven et al., 2000; Afzal et al., 2003; 
Schwabe et al., 2004). This is seen within 
developmentally regulated features such as the 
formation of bones in the face and limbs. 
2) BDB is an autosomal dominant disorder that arises 
from truncations of the kinase domains - either 
truncation of the serine/threonine domains and proline 
rich domain just below the Tyr kinase domain; or 
truncation of the entire intracellular domain right just 
below the transmembrane domain (Oldridge et al., 
2000). Patients that present with BDB have abnormally 
short digits with the 4th and 5th digits particularly 
affected and have malformed or absent finger and toe 
nails (Schwabe et al., 2000; Afzal et al., 2003). 
Somatic 
Kubo et al. has reported somatic mutations in ROR2 in 




ROR2 has been identified in poorly differentiated 
invasive gastric cancer and in intestinal-type and 
diffuse-type gastric cancers. ROR2 is identified as a 
frequent target of somatic mutations in poorly 
differentiated invasive gastric cancers (Kubo et al.,
2009). In intestinal-type and diffuse-type gastric 
cancers, ROR2 is shown to play a role in cell invasion 
and is also downstream of the crosstalk between the 




ROR2 was found to be overexpressed in a majority of 
metastatic malignant melanomas and also found to 
have a dramatic impact on cell motility, cell invasion 
and metastasis. Additionally, ROR2 expression was 
found to be correlated with Wnt5a expression in 
metastatic melanoma (O'Connell et al., 2010). 
Osteosarcoma 
Note 
ROR2 overexpression has been described in this 
adolescent bone cancer. ROR2 is transactivated in a 
majority of osteosarcoma and also plays a role in cell 
migration and cell proliferation (Morioka et al., 2009). 
Evidence links Wnt5a and ROR2 within osteosarcoma 
where ROR2 has additional ties to having a role in the 
degradation of the extracellular matrix and invadopia 
formation (Enomoto et al., 2009). 
Prostate cancer 
Note 
ROR2 has also been linked to prostate cancer via 
Wnt5a interaction. In prostate cancer, evidence 
suggests that Wnt5a utilizes ROR2 or Frizzled 2 as a 
receptor for its invasive potential. Further, it was shown 
that the Wnt5a/ROR2 receptor complex has a role in 
cell invasion (Yamamoto et al., 2010). 
Renal cell carcinoma 
Note 
ROR2 was found to be overexpressed in the majority f 
renal cell carcinoma primary tumors. This aberrantly 
overexpressed kinase was shown to support cell 
migration, affect anchorage independent growth and 
promote xenograft tumor growth in renal cell 
carcinoma cell lines (Wright et al., 2009). 
Squamous cell carcinoma 
Note 
ROR2 has been shown to be more highly invasive in 
oral malignant cancer epithelial cells than normal 
mucosa. In this cancer, ROR2 is associated with 
increased cell polarity and cell motility (Kobayashi et 
al., 2009). 
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